Insulin and diabetes drug manufacturers charged with federal and state price-fixing violations over their 340B contract pharmacy restrictions have again told a federal judge why they think she should dismiss the case.
Insulin and diabetes drug manufacturers charged with federal and state price-fixing violations over their 340B contract pharmacy restrictions have again told a federal judge why they think she should dismiss the case.
*Sign up for news summaries and alerts from 340B Report